Galectin completes enrollment in NAVIGATE Phase 2b/3 belapectin study for NASH cirrhosis

GALECTIN THERAPEUTICS INC

309 patients randomized to date; expects 325-340 total by early March 2023.
Phase 2b portion studies belapectin 2 mg/kg and 4 mg/kg vs. placebo (1:1:1).
Primary endpoint: primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.
Interim analysis results expected in Q4 2024 after 18-month treatment period.
Study recruited patients across 14 countries and five continents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.